Moberg Pharma AB (publ)

Stockholm Stock Exchange MOB.ST

Moberg Pharma AB (publ) Gross Profit Margin for the year ending December 31, 2023

Moberg Pharma AB (publ) Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Moberg Pharma AB (publ) Gross Profit Margin for the year ending December 31, 2022 was -1,147.34%.
Moberg Pharma AB (publ) Gross Profit Margin for the year ending December 31, 2020 was 100.00%, a 31.21% change year over year.
Moberg Pharma AB (publ) Gross Profit Margin for the year ending December 31, 2018 was 76.21%, a 6.61% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Stockholm Stock Exchange: MOB.ST

Moberg Pharma AB (publ)

CEO	Ms. Anna Ljung BA, M.Sc.
IPO Date	May 26, 2011
Location	Sweden
Headquarters	GustavslundsvAegen 42
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

Key trends

Past 5 years